Autoinflammatory & rare systemic diseases
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database
Authors' conclusion
This interim analysis showed a good maintenance of canakinumab treatment 2 years after initiation and confirmed its safety profile in real-life practice in France in patients diagnosed with FMF, MKD and TRAPS.
Study context
- Population
- French patients diagnosed with Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD) or TRAPS and treated with canakinumab, from the JIR cohort (multicentre international registry of juvenile inflammatory rheumatic diseases)
- Participants
- 31 / 26 / 7
- Exposure
- FMF vs MKD vs TRAPS
- FMFn = 31
- MKDn = 26
- TRAPSn = 7
- Outcome
- Patients still on canakinumab treatment
- Follow-up
- 2 years after initiation
Methodological detailsreal-world evidence, multicentre, interim analysis
- Real-world evidence
- Multicentre
- Interim analysis
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Treatment patterns (dose and frequency)
- Most initiated at recommended dose of 2 mg/kg or 150 mg
- Less than half of FMF and MKD patients initiated at recommended frequency (every 4 weeks)
- Dose per injection globally unchanged over treatment; some adjustments of dose intervals
Safety
- Patients with a severe adverse event
- 6
- Severe adverse events possibly related to canakinumab
- 3
Original publication
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database. Arthritis Res Ther. Published 8 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →